FIELD : medicine.SUBSTANCE : invention relates to the field of medicine, namely to oncogynecology. Essence of the method : biological samples are taken with HPV-negative, HPV16- and HPV18-positive cervical cancer of the II-III stage, then, the number of viral genes E7 and E2 is determined by real-time polymerase chain reaction, according to their ratio (E7/E2), taking into account the coefficient of variation (CV%) and standard deviation for three repeats, the presence of HPV16 DNA or 18 type is determined. If HPV VKR not detected, then predict adverse clinical outcome of the disease; ratio of viral genes E7/E2≥1.3 with CV%10?% in HPV16/18-positive patients, which corresponds to the presence of the integration of the virus DNA into the cell genome, an adverse clinical outcome of the disease is predicted; ratio of viral genes E7/E2<1.3 with CV%≤10?% – in HPV16/18-positive patients, which corresponds to the lack of integration of the virus DNA into the cell genome, then a favorable clinical outcome of the disease is predicted.EFFECT : invention and can be used to predict the clinical outcome of locally advanced cervical cancer (stage II-III).1 cl, 10 ex, 3 tbl, 7 dwg